Verified Nov 2026
Other
·

Baar, Canton of Zug
·
Since 2015
Stallergenes Greer is a Swiss biopharmaceutical company headquartered in Baar, founded in 2015 through a merger combining over 120 years of expertise. With 1,000–5,000 employees and estimated revenue of $250–500M, it develops and manufactures allergen immunotherapy treatments across 46 countries. The company operates global manufacturing capacity for allergen and immunotherapy products, serving allergy specialists and healthcare professionals worldwide.
Stallergenes Greer at a glance
Revenue
$250-500M
Est. band
Employees
1,000-5,000
Founded
2015
Headquarters
Baar, Canton of Zug
Industries
Automotive
Electric Vehicles
Medical
Industrial Equipment
Overview
Stallergenes Greer is a Swiss biopharmaceutical company headquartered in Baar, founded in 2015 through a merger combining over 120 years of expertise. With 1,000–5,000 employees and estimated revenue of $250–500M, it develops and manufactures allergen immunotherapy treatments across 46 countries. The company operates global manufacturing capacity for allergen and immunotherapy products, serving allergy specialists and healthcare professionals worldwide.
At a glance
Attribute | Detail |
|---|---|
Founded | 2015 |
Headquarters | Baar, Canton of Zug |
Employees | 1,000-5,000 |
Revenue | $250-500M (estimated) |
What Stallergenes Greer makes
Stallergenes Greer offers subcutaneous injections, sublingual drops, sublingual tablets, and diagnostic components including enzyme-linked immunosorbent assay for severe allergic rhinitis and asthma.
Latest developments
2026-06-26 — Press releases | Stallergenes Greer (stallergenesgreer.com)
2026-06-26 — Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 2026 | Morningstar (morningstar.com)
2026-06-01 — Stallergenes Greer invests more than €125 million in France | Stallergenes Greer (stallergenesgreer.com)
2026-03-17 — Stallergenes Greer has reached an important step in China six months after signing the agreement with Nuance Pharma: the first patient in Macau has received treatment for Actair® within the framework of … | Stallergenes Greer (linkedin.com)
2026-01-07 — Stallergenes Greer expands venom immunotherapy production capacity with acquisition of ENTOMON S.R.L. | Stallergenes Greer (stallergenesgreer.com)
2025-10-30 — Staloral®Birch Phase III study successfully meets primary endpoint, demonstrating efficacy in children and adolescents | Stallergenes Greer (stallergenesgreer.com)
Company details
The company operates significant production facilities in London, UK and North Carolina, USA, alongside its Swiss headquarters, and established market presence in China through a partnership agreement signed in 2025. Stallergenes Greer was founded in 2015, has an estimated 1,000-5,000 employees, and is headquartered in Baar, Canton of Zug.
Frequently asked questions
What does Stallergenes Greer do?
Stallergenes Greer is a Swiss biopharmaceutical company headquartered in Baar, founded in 2015 through a merger combining over 120 years of expertise. With 1,000–5,000 employees and estimated revenue of $250–500M, it develops and manufactures allergen immunotherapy treatments across 46 countries. The company operates global manufacturing capacity for allergen and immunotherapy products, serving allergy specialists and healthcare professionals worldwide.
Where is Stallergenes Greer headquartered?
Stallergenes Greer is headquartered in Baar, Canton of Zug (76b Zugerstrasse, Baar, Canton of Zug, 6340).
When was Stallergenes Greer founded?
Stallergenes Greer was founded in 2015.
How big is Stallergenes Greer?
Stallergenes Greer has an estimated 1,000-5,000 employees, with revenue in the $250-500M range (estimated).
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.
